Abiopharma

LEXEO THERAPEUTICS, INC. (LXEO)

Symbol	LXEO
Name	LEXEO THERAPEUTICS, INC.
Sector	HEALTH CARE
Region	North America
Industry	Biotechnology: Biological Products (No Diagnostic Substances)
Address	345 PARK AVENUE SOUTH,6TH FLOOR, NEW YORK, New York, 10010, United States
Telephone	212-547-9879
Fax	—
Email	—
Website	https://www.lexeotx.com
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	0001907108
Description	Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreichs ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York. Additional info from NASDAQ: Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreichs ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

2026-06-29 20:45

Altschuler Steven 🟢 acquired 35.0K shares (1 derivative) of Lexeo Therapeutics, Inc. (LXEO) at $4.70 Transaction Date: Jun 25, 2026 | Filing ID: 000002

2026-06-29 20:45

Agger Mette Kirstine 🟢 acquired 35.0K shares (1 derivative) of Lexeo Therapeutics, Inc. (LXEO) at $4.70 Transaction Date: Jun 25, 2026 | Filing ID: 000002

2026-06-29 20:44

COOPERSTONE BRENDA 🟢 acquired 35.0K shares (1 derivative) of Lexeo Therapeutics, Inc. (LXEO) at $4.70 Transaction Date: Jun 25, 2026 | Filing ID: 000002

2026-06-29 20:43

DIAZ REINALDO M 🟢 acquired 35.0K shares (1 derivative) of Lexeo Therapeutics, Inc. (LXEO) at $4.70 Transaction Date: Jun 25, 2026 | Filing ID: 000002

2026-06-29 20:41

Van Hauwermeiren Timothy 🟢 acquired 35.0K shares (1 derivative) of Lexeo Therapeutics, Inc. (LXEO) at $4.70 Transaction Date: Jun 25, 2026 | Filing ID: 000005

2026-06-29 20:40

CHOLMONDELEY PAULA H 🟢 acquired 35.0K shares (1 derivative) of Lexeo Therapeutics, Inc. (LXEO) at $4.70 Transaction Date: Jun 25, 2026 | Filing ID: 000002

2026-06-17 20:01

Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia

2026-06-15 11:00

Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia

2026-05-20 20:30

Otero Jose Manuel 🔴 sold 1.3K shares of Lexeo Therapeutics, Inc. (LXEO) at $5.07 Transaction Date: May 18, 2026 | Filing ID: 000009

2026-05-20 20:30

Townsend Richard Nolan 🔴 sold 3.3K shares of Lexeo Therapeutics, Inc. (LXEO) at $5.06 Transaction Date: May 18, 2026 | Filing ID: 000011

Trial ID	Title	Phase	Indication	Status	Start Date	Completion Date	Source
NCT06865482	Clinical Course Of Disease In Participants With FA-CM	—	Friedreich Ataxia	Recruiting	2025-09-30	2027-09-01	ClinicalTrials.gov
NCT07050160	Long-term Follow-up Study of Gene Therapy for Arrhythmogenic Cardiomyopathy Due…	—	Arrhythmogenic Cardiomyopathy	Enrolling_By_Invitation	2025-08-29	2030-08-01	ClinicalTrials.gov
NCT06109181	Gene Therapy for ACM Due to a PKP2 Pathogenic Variant	Phase1	Arrhythmogenic Cardiomyopathy	Active_Not_Recruiting	2024-02-29	2027-03-01	ClinicalTrials.gov
NCT06976606	A Study to Assess Real-world Patient Characteristics and Clinical Course for Sy…	—	Arrhythmogenic Cardiomyopathy	Recruiting	2024-01-23	2027-09-01	ClinicalTrials.gov
NCT05400330	Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease	Phase1	Alzheimer Disease	Active_Not_Recruiting	2023-05-08	2028-11-01	ClinicalTrials.gov
NCT05445323	Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia	Phase1	Friedreich Ataxia	Active_Not_Recruiting	2022-08-24	2029-09-01	ClinicalTrials.gov
NCT03634007	Gene Therapy for APOE4 Homozygote of Alzheimer's Disease	Phase1	Alzheimer Disease	Completed	2019-11-06	2024-11-07	ClinicalTrials.gov

Total clinical trials: 7

Product Name	Type	Development Stage	Therapeutic Area	Study Status	Trial ID
LX1001	Other	Phase PHASE1	Alzheimer Disease	ACTIVE_NOT_RECRUITING	NCT05400330
LX1001	Other	Phase PHASE1	Alzheimer Disease	COMPLETED	NCT03634007
LX2020	Other	Phase PHASE1	Arrhythmogenic Cardiomyopathy	ACTIVE_NOT_RECRUITING	NCT06109181
High Dose LX2006	Other	Phase PHASE1	Friedreich Ataxia	ACTIVE_NOT_RECRUITING	NCT05445323
Mid Dose LX2006	Other	Phase PHASE1	Friedreich Ataxia	ACTIVE_NOT_RECRUITING	NCT05445323
Low dose LX2006	Other	Phase PHASE1	Friedreich Ataxia	ACTIVE_NOT_RECRUITING	NCT05445323

Total products: 6